ScreenerHero

INMBINmune Bio, Inc.

NAS · US · Healthcare · Biotechnology · inmunebio.com
2.320USD+4.04%Mkt Cap: 64.39M $P/E: —

INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product cand…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap64.39M $
Enterprise Value42.94M $
Revenue (TTM)0 $
Gross Profit0 $
Net Income (TTM)-45.93M $
Revenue/Share0.0000 USD
Last Price2.320 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees21
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.41
PEG—
EV/EBITDA—
EV/Revenue—
P/SInfinity
P/B2.93
EPS (TTM)-0.60
EPS (Forward)-0.49
52W Range
1.09083% of range2.580
52W High2.580 USD
52W Low1.090 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-91866.00%
ROE-195.26%
ROA-141.98%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-22.58M $
CapEx (TTM)1.04M $
FCF Margin—
FCF Yield-15.60%
Net Debt-17.01M $
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.04
Current Ratio4.04
Quick Ratio3.94
Book Value/Sh0.7360 USD
Cash/Share0.6630 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.000 USD
Upside (mean)+201.7%
Target Range4.000 USD – 9.000 USD
$4.000+201.7% to mean$9.000
# Analysts4
Ownership
Shares Out.27.75M
Float23.30M
Insiders10.75%
Institutions15.57%
Short Interest
Short Ratio3.3d
Short % Float8.93%
Short % Out.7.97%
Shares Short2.20M
Short (prev mo.)3.07M
Technical
SMA 501.762 (+31.7%)
SMA 2001.559 (+48.8%)
Beta0.90
S&P 52W Chg18.16%
Avg Vol (30d)512.30K
Avg Vol (10d)419.21K
Technical Indicators
RSI (14)71.1
MACD0.1329
MACD Signal0.1065
MACD Hist.+0.0263
BB Upper2.353 USD
BB Middle1.941 USD
BB Lower1.529 USD
BB Width42.47%
ATR (14)0.1329 USD
Vol Ratio (20d)1.57x